JPWO2020146535A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020146535A5 JPWO2020146535A5 JP2021539682A JP2021539682A JPWO2020146535A5 JP WO2020146535 A5 JPWO2020146535 A5 JP WO2020146535A5 JP 2021539682 A JP2021539682 A JP 2021539682A JP 2021539682 A JP2021539682 A JP 2021539682A JP WO2020146535 A5 JPWO2020146535 A5 JP WO2020146535A5
- Authority
- JP
- Japan
- Prior art keywords
- headache
- days
- month
- seq
- overuse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010019233 Headaches Diseases 0.000 claims description 91
- 229920001184 polypeptide Polymers 0.000 claims description 69
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 69
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 69
- 231100000869 headache Toxicity 0.000 claims description 67
- 239000003814 drug Substances 0.000 claims description 63
- 229940079593 drug Drugs 0.000 claims description 61
- 208000017143 Secondary Headache disease Diseases 0.000 claims description 54
- 206010027599 migraine Diseases 0.000 claims description 43
- 208000019695 Migraine disease Diseases 0.000 claims description 40
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 40
- 206010072720 Medication overuse headache Diseases 0.000 claims description 37
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 37
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 34
- 229940121367 non-opioid analgesics Drugs 0.000 claims description 34
- 239000000730 antalgic agent Substances 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 25
- 230000001154 acute effect Effects 0.000 claims description 24
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 23
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 22
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 20
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 20
- 229960004126 codeine Drugs 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 17
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims description 17
- 229960001113 butorphanol Drugs 0.000 claims description 17
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 17
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 17
- 229960000240 hydrocodone Drugs 0.000 claims description 17
- 229960005181 morphine Drugs 0.000 claims description 17
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 17
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 17
- 229960003708 sumatriptan Drugs 0.000 claims description 17
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 17
- 229960004380 tramadol Drugs 0.000 claims description 17
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 17
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 17
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 16
- 229940005483 opioid analgesics Drugs 0.000 claims description 15
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 14
- 229960002085 oxycodone Drugs 0.000 claims description 14
- 238000002636 symptomatic treatment Methods 0.000 claims description 14
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 claims description 13
- 229960002133 almotriptan Drugs 0.000 claims description 13
- 229960002472 eletriptan Drugs 0.000 claims description 13
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 claims description 13
- 229960002284 frovatriptan Drugs 0.000 claims description 13
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 claims description 13
- 229960005254 naratriptan Drugs 0.000 claims description 13
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims description 13
- 229960000425 rizatriptan Drugs 0.000 claims description 13
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims description 13
- 229960004943 ergotamine Drugs 0.000 claims description 12
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 claims description 12
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 claims description 12
- 229960005489 paracetamol Drugs 0.000 claims description 12
- 238000002483 medication Methods 0.000 claims description 11
- 230000000202 analgesic effect Effects 0.000 claims description 10
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 claims description 10
- 229960001360 zolmitriptan Drugs 0.000 claims description 10
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims description 10
- 229940035676 analgesics Drugs 0.000 claims description 9
- 208000011117 substance-related disease Diseases 0.000 claims description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960001948 caffeine Drugs 0.000 claims description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 8
- 201000009032 substance abuse Diseases 0.000 claims description 8
- 208000027109 Headache disease Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 231100000736 substance abuse Toxicity 0.000 claims description 5
- 206010013654 Drug abuse Diseases 0.000 claims description 4
- 229940125717 barbiturate Drugs 0.000 claims description 4
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 4
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002546 butalbital Drugs 0.000 claims description 4
- 208000006561 Cluster Headache Diseases 0.000 claims description 3
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 3
- 230000001667 episodic effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 description 161
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 33
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 18
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 18
- 229920000053 polysorbate 80 Polymers 0.000 description 18
- 229940068968 polysorbate 80 Drugs 0.000 description 18
- 239000000600 sorbitol Substances 0.000 description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 16
- 229960002885 histidine Drugs 0.000 description 15
- 241000235058 Komagataella pastoris Species 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- -1 dexbuprofen Chemical compound 0.000 description 5
- 229960003133 ergot alkaloid Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 229960004193 dextropropoxyphene Drugs 0.000 description 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- YHELUJCERLGVBD-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)-1-phenyl-6,7-dihydro-5h-pyrrolizin-3-yl]acetic acid Chemical compound C=12CCCN2C(CC(=O)O)=C(C=2C=CC(Cl)=CC=2)C=1C1=CC=CC=C1 YHELUJCERLGVBD-UHFFFAOYSA-N 0.000 description 1
- SZSLUWXHMBOZRZ-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-hydroxybenzamide;n-(4-hydroxyphenyl)acetamide;1,3,7-trimethylpurine-2,6-dione Chemical compound NC(=O)C1=CC=CC=C1O.CC(=O)NC1=CC=C(O)C=C1.CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C SZSLUWXHMBOZRZ-UHFFFAOYSA-N 0.000 description 1
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical compound C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 description 1
- MLQRZXNZHAOCHQ-UHFFFAOYSA-N 3-methylfentanyl Chemical group C=1C=CC=CC=1N(C(=O)CC)C(C(C1)C)CCN1CCC1=CC=CC=C1 MLQRZXNZHAOCHQ-UHFFFAOYSA-N 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 description 1
- 229940126700 Excedrin Migraine Drugs 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- FNAHUZTWOVOCTL-XSSYPUMDSA-N Heterocodeine Chemical compound C([C@@H](N(CC1)C)[C@@H]2C=C[C@@H]3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 FNAHUZTWOVOCTL-XSSYPUMDSA-N 0.000 description 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- ZKLXUUYLEHCAMF-UUWFMWQGSA-N Oripavine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ZKLXUUYLEHCAMF-UUWFMWQGSA-N 0.000 description 1
- ZKLXUUYLEHCAMF-UHFFFAOYSA-N Oripavine Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(O)C5=C4C23C1O5 ZKLXUUYLEHCAMF-UHFFFAOYSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 244000082490 Proboscidea louisianica Species 0.000 description 1
- 235000015926 Proboscidea louisianica ssp. fragrans Nutrition 0.000 description 1
- 235000015925 Proboscidea louisianica subsp. louisianica Nutrition 0.000 description 1
- 235000019096 Proboscidea parviflora Nutrition 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- TYRXZVFTBRIZFW-LTQSXOHQSA-N [(4r,4ar,7s,7ar,12bs)-9-benzoyloxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-yl] benzoate Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=CC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CC=C1 TYRXZVFTBRIZFW-LTQSXOHQSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- JDTRGWXTYWXUHP-UHFFFAOYSA-N acetylpropionylmorphine Chemical compound CCC(=O)OC1C=CC2C(N(CC3)C)CC4=CC=C(OC(C)=O)C5=C4C23C1O5 JDTRGWXTYWXUHP-UHFFFAOYSA-N 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- KGYFOSCXVAXULR-UHFFFAOYSA-N allylprodine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCN(C)CC1CC=C KGYFOSCXVAXULR-UHFFFAOYSA-N 0.000 description 1
- 229950004361 allylprodine Drugs 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical group C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 description 1
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 description 1
- 229960001209 clonixin Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- BCQMRZRAWHNSBF-UHFFFAOYSA-N desmethylprodine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCN(C)CC1 BCQMRZRAWHNSBF-UHFFFAOYSA-N 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 229950003851 desomorphine Drugs 0.000 description 1
- 229960002783 dexketoprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 1
- NCXVKLDKUADJPV-PVHGPHFFSA-N diacetyldihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O NCXVKLDKUADJPV-PVHGPHFFSA-N 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- KDFWILUISXRMIK-LISRSHBKSA-N dipropanoylmorphine Chemical compound C1C2=C(C(=O)CC)C(C(=O)CC)=C(O)C3=C2[C@@]24CCN(C)[C@H]1[C@@H]4C=C[C@H](O)[C@@H]2O3 KDFWILUISXRMIK-LISRSHBKSA-N 0.000 description 1
- 229940105576 disalcid Drugs 0.000 description 1
- 229940072701 dolobid Drugs 0.000 description 1
- 229960001850 droxicam Drugs 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 229960004578 ethylmorphine Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229950004155 etorphine Drugs 0.000 description 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 1
- 229940085392 excedrin Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229960003029 ketobemidone Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- 229960004300 nicomorphine Drugs 0.000 description 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- BVURVTVDNWSNFN-UHFFFAOYSA-N pepap Chemical compound C1CC(OC(=O)C)(C=2C=CC=CC=2)CCN1CCC1=CC=CC=C1 BVURVTVDNWSNFN-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- UVAZQQHAVMNMHE-CJNGLKHVSA-N prodine Chemical compound C=1C=CC=CC=1[C@]1(OC(=O)CC)CCN(C)C[C@H]1C UVAZQQHAVMNMHE-CJNGLKHVSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 229960003394 remifentanil Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 description 1
- 229930003945 thebaine Natural products 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024195562A JP2025032102A (ja) | 2019-01-08 | 2024-11-08 | 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789828P | 2019-01-08 | 2019-01-08 | |
| US62/789,828 | 2019-01-08 | ||
| US201962840967P | 2019-04-30 | 2019-04-30 | |
| US62/840,967 | 2019-04-30 | ||
| US201962841585P | 2019-05-01 | 2019-05-01 | |
| US62/841,585 | 2019-05-01 | ||
| US201962872983P | 2019-07-11 | 2019-07-11 | |
| US62/872,983 | 2019-07-11 | ||
| PCT/US2020/012790 WO2020146535A1 (en) | 2019-01-08 | 2020-01-08 | Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195562A Division JP2025032102A (ja) | 2019-01-08 | 2024-11-08 | 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516957A JP2022516957A (ja) | 2022-03-03 |
| JPWO2020146535A5 true JPWO2020146535A5 (https=) | 2022-12-13 |
| JP2022516957A5 JP2022516957A5 (https=) | 2022-12-13 |
Family
ID=71404208
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539682A Withdrawn JP2022516957A (ja) | 2019-01-08 | 2020-01-08 | 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療 |
| JP2024195562A Pending JP2025032102A (ja) | 2019-01-08 | 2024-11-08 | 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195562A Pending JP2025032102A (ja) | 2019-01-08 | 2024-11-08 | 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20200216525A1 (https=) |
| EP (1) | EP3908607A4 (https=) |
| JP (2) | JP2022516957A (https=) |
| KR (1) | KR20210114002A (https=) |
| CN (2) | CN119303074A (https=) |
| AU (1) | AU2020207299A1 (https=) |
| BR (1) | BR112020018044A2 (https=) |
| CA (1) | CA3123292A1 (https=) |
| CL (1) | CL2021001813A1 (https=) |
| CO (1) | CO2021008665A2 (https=) |
| DO (1) | DOP2021000145A (https=) |
| EC (1) | ECSP21052193A (https=) |
| GE (2) | GEP20257804B (https=) |
| IL (1) | IL284677A (https=) |
| JO (1) | JOP20210166A1 (https=) |
| MA (1) | MA54709A (https=) |
| MX (1) | MX2021008268A (https=) |
| NI (1) | NI202100063A (https=) |
| PE (1) | PE20211708A1 (https=) |
| PH (1) | PH12021551494A1 (https=) |
| SG (1) | SG11202106878XA (https=) |
| TW (1) | TW202030205A (https=) |
| UA (1) | UA129265C2 (https=) |
| WO (1) | WO2020146535A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012258980B8 (en) | 2011-05-20 | 2017-06-15 | H. Lundbeck A/S | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| TWI685505B (zh) | 2011-05-20 | 2020-02-21 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 |
| NZ717704A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| CN113227140A (zh) | 2019-01-08 | 2021-08-06 | H.隆德贝克有限公司 | 使用抗cgrp抗体急性治疗和快速治疗头痛 |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| EP4392447A1 (en) * | 2021-08-27 | 2024-07-03 | H. Lundbeck A/S | Treatment of cluster headache using anti-cgrp antibodies |
| WO2024032750A1 (zh) * | 2022-08-11 | 2024-02-15 | 上海君实生物医药科技股份有限公司 | 抗cgrp抗体及用途 |
| CN118476508A (zh) * | 2024-06-27 | 2024-08-13 | 中国人民解放军总医院第一医学中心 | 一种基于疾病发生特点的药物过度使用性头痛动物模型的构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070065463A1 (en) * | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
| AU2012258980B8 (en) * | 2011-05-20 | 2017-06-15 | H. Lundbeck A/S | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| TWI685505B (zh) * | 2011-05-20 | 2020-02-21 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 |
| CN103585449B (zh) * | 2013-10-23 | 2016-06-22 | 高丽丽 | 用于治疗偏头痛的中药组合物 |
| CA2982861A1 (en) * | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
| WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| WO2018055574A1 (en) * | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| CN113227140A (zh) * | 2019-01-08 | 2021-08-06 | H.隆德贝克有限公司 | 使用抗cgrp抗体急性治疗和快速治疗头痛 |
-
2020
- 2020-01-08 PE PE2021001141A patent/PE20211708A1/es unknown
- 2020-01-08 CN CN202411285298.5A patent/CN119303074A/zh active Pending
- 2020-01-08 CA CA3123292A patent/CA3123292A1/en active Pending
- 2020-01-08 GE GEAP202015689A patent/GEP20257804B/en unknown
- 2020-01-08 MA MA054709A patent/MA54709A/fr unknown
- 2020-01-08 WO PCT/US2020/012790 patent/WO2020146535A1/en not_active Ceased
- 2020-01-08 US US16/736,937 patent/US20200216525A1/en not_active Abandoned
- 2020-01-08 GE GEAP202515689A patent/GEAP202515689A/en unknown
- 2020-01-08 JP JP2021539682A patent/JP2022516957A/ja not_active Withdrawn
- 2020-01-08 CN CN202080007409.XA patent/CN113272324A/zh active Pending
- 2020-01-08 EP EP20738512.1A patent/EP3908607A4/en active Pending
- 2020-01-08 AU AU2020207299A patent/AU2020207299A1/en active Pending
- 2020-01-08 JO JOP/2021/0166A patent/JOP20210166A1/ar unknown
- 2020-01-08 BR BR112020018044-0A patent/BR112020018044A2/pt unknown
- 2020-01-08 KR KR1020217023581A patent/KR20210114002A/ko active Pending
- 2020-01-08 MX MX2021008268A patent/MX2021008268A/es unknown
- 2020-01-08 TW TW109100630A patent/TW202030205A/zh unknown
- 2020-01-08 PH PH1/2021/551494A patent/PH12021551494A1/en unknown
- 2020-01-08 SG SG11202106878XA patent/SG11202106878XA/en unknown
- 2020-01-08 UA UAA202104194A patent/UA129265C2/uk unknown
-
2021
- 2021-06-30 CO CONC2021/0008665A patent/CO2021008665A2/es unknown
- 2021-07-07 CL CL2021001813A patent/CL2021001813A1/es unknown
- 2021-07-07 DO DO2021000145A patent/DOP2021000145A/es unknown
- 2021-07-07 IL IL284677A patent/IL284677A/en unknown
- 2021-07-07 NI NI202100063A patent/NI202100063A/es unknown
- 2021-07-14 EC ECSENADI202152193A patent/ECSP21052193A/es unknown
-
2023
- 2023-11-16 US US18/511,241 patent/US20240343784A1/en active Pending
-
2024
- 2024-11-08 JP JP2024195562A patent/JP2025032102A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vadivelu et al. | Ketorolac tromethamine–routes and clinical implications | |
| Blondell et al. | Pharmacologic therapy for acute pain | |
| Leppert | The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities [Polish version: Wpływ opioidowych środków przeciwbólowych na czynność układu pokarmowego oraz aktualne możliwości postępowania terapeutycznego p. 132] | |
| Beaver | Combination analgesics | |
| JP5835865B2 (ja) | ロキソプロフェン含有医薬組成物 | |
| JP2009539761A5 (https=) | ||
| JP5897804B2 (ja) | ロキソプロフェン含有の医薬組成物 | |
| JPWO2020146535A5 (https=) | ||
| AU2025271432A1 (en) | CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo | |
| Herrero et al. | Antinociception and the new COX inhibitors: research approaches and clinical perspectives | |
| US20170281534A1 (en) | Administration of intravenous ibuprofen | |
| Desjardins et al. | A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain | |
| Chang et al. | Comparison of rofecoxib and a multidose oxycodone/acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial | |
| CN106999454A (zh) | 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛 | |
| Raffa et al. | Oxycodone combinations for pain relief | |
| Kraft | Emerging pharmacologic options for treating postoperative ileus | |
| Gershell et al. | Making gains in pain. | |
| TW202019484A (zh) | 調節對鴉片、鴉片類或鴉片止痛劑之耐受性及治療急性及慢性疼痛之方法及組合 | |
| US9707225B2 (en) | Combinations of opioid/TLR4 antagonist and acetyl-para-aminophenol (APAP) for use in the treatment of pain | |
| AU2020218253A1 (en) | Pharmaceutical compositions comprising meloxicam | |
| Reisner-Keller | Pharmacotherapeutics in the management of orofacial pain | |
| Thanoon et al. | Evaluation the combination of chlorpheniramine and tramadol at a level of thermal and visceral antinociceptive in a mouse acute pain model. | |
| Chu et al. | Molecular basis and clinical implications of opioid tolerance and opioid-induced hyperalgesia | |
| US20090270400A1 (en) | Painkilling association comprising a dihydroimidazopyrazine derivative | |
| Tedeschi | Naltrexone for opioid dependence: an additional tool for general practitioners |